Group 1 - Ero Copper's Tucuma copper project in Brazil has commenced commercial production, but analysts express skepticism about the company's ability to meet its annual production targets [1][2] - In Q2, the Tucuma project produced approximately 6,400 tons of copper, with about 2,000 tons produced in the latter half of June [1][2] - The project is expected to reach a copper production of 37,500-42,500 pounds by 2025, which represents half of Ero's annual guidance of 75,000-85,000 pounds [2] Group 2 - Scotia Capital analysts indicate that Ero's copper production in the first half of the year was only 11,467 tons, raising concerns about achieving the 2025 guidance [2] - Ero reported that the Tucuma processing plant's throughput exceeded 75% of its design capacity last month, with metallurgical recovery rates and copper concentrate grades meeting or exceeding design targets [2][3] - The company has resolved bottleneck issues identified at the end of 2024 through recent maintenance work, which is expected to enhance throughput and mitigate the impact of declining copper grades [3] Group 3 - Ero's estimated cash costs for copper production this year are projected to be between $1.05 and $1.25 per pound [4] - Analysts expect significant free cash flow generation in the second half of the year, potentially exceeding $50 million, allowing Ero to focus on deleveraging its balance sheet and supporting shareholder returns [4]

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 上海证券交易所： 根据贵所《关于迈威（上海）生物科技股份有限公司2024年报告的信息披 露监管问询函》（上证科创公函【2025】0064号）（以下简称"《问询函》"） 的要求，国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"） 作为迈威（上海）生物科技股份有限公司（以下简称"公司"）首次公开发行 股票并在科创板上市的保荐机构及持续督导机构，对问询函相关问题进行了审 慎核查，并出具核查意见如下： 本核查意见中若出现总计数尾数与所列数值总和尾数不符的情况，均为四 舍五入所致。本核查意见中所列示的包括但不限于收入、利润及产能规划等数 据的相关测算和预计均不构成业绩承诺或盈利预测。如无特别说明，本核查意 见中使用的简称或名词释义与《迈威（上海）生物科技股份有限公司2024年年 度报告》（以下简称"2024年报"）一致。 问题一 关于经营业绩 关于经营业绩。年报显示，2024 年公司实现营业收入 2.00 亿元，同比增长 面，公司已有君迈康、迈利舒、迈卫健等 3 款产品获批上市，其中君迈康全年 发货 48,821 支，同比下降 66.61%，迈 ...